<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953849</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-003-09S</org_study_id>
    <nct_id>NCT00953849</nct_id>
  </id_info>
  <brief_title>Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity</brief_title>
  <official_title>Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The poor survival of Veterans with oral cancer underscores the significance of identifying
      new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic
      approach for oral cancer patients which lessen the immune inhibitory environment while
      maturing cells that can stimulate T cell reactivity against oral cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is beneficial T cell reactivity in oral squamous cell carcinoma
      (OSCC) tumors can be synergistically stimulated by blocking suppressor endothelial cells and
      their induction of other inhibitory cell populations while also maturing immune inhibitory
      CD34+ cells into antigen-presenting dendritic cells.

      To test this hypothesis, newly diagnosed OSCC patients will be administered the
      cyclooxigenase 2 inhibitor celecoxib and/or Calcitriol for the 3 week duration between cancer
      diagnosis and surgical treatment. The following aims will test the immunological and clinical
      effectiveness of the combination treatment:

        -  1. To block the suppressive activity of endothelial cells and increase the levels of
           dendritic that are stimulatory to T cell reactivity, thereby synergistically increasing
           intratumoral T cell reactivity. These functional immune analyses will use OSCC tissues
           removed from untreated patients or patients treated with celecoxib and/or Calcitriol.

        -  2. To reduce development of OSCC recurrences by synergistically stimulating intratumoral
           T cell reactivity with celecoxib to block suppressor endothelial cell activity and
           Calcitriol to mature CD34+ suppressor cells into T cell stimulatory dendritic cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IL-2 Levels</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Change in IL-2 stimulatory cytokine levels within tumor tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IFN-gamma Levels</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Change in IFN-gamma stimulatory cytokine levels within tumor tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in GM-CSF</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Change in GM-CSF stimulatory cytokine levels within tumor tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-6 Levels.</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Change in levels of immune inhibitory/inflammatory mediator IL-6 in tumor tissue.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Mouth Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1: Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib treatment prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Calcitriol prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Celecoxib plus Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Celecoxib plus Calcitriol prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib (400 mg twice daily)</description>
    <arm_group_label>Arm 1: Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)</description>
    <arm_group_label>Arm 2: Calcitriol</arm_group_label>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib plus Calcitriol</intervention_name>
    <description>3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)</description>
    <arm_group_label>Arm 3: Celecoxib plus Calcitriol</arm_group_label>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locoregional OSCC (T stage II-IV) of the oral cavity, oropharynx, larynx, or
             hypopharynx without evidence of distant metastases

          -  greater than or equal to 18 years of age

          -  the OSCC treatment plan includes surgical resection

          -  performance status of 0 or 1

          -  recovered from any prior surgery

          -  must be willing to use appropriate contraception if of child-bearing potential

          -  give signed informed consent prior to the initiation of therapy

        Exclusion Criteria:

          -  prior immunotherapy

          -  chemotherapy or radiation therapy within three weeks

          -  concurrent NSAID treatments while undergoing treatment

          -  women pregnant or lactating

          -  HIV positive

          -  have an active infection requiring antibiotic therapy, or concomitant malignancies

          -  history of idiopathic urinary calcium stone disease, chronic hypercalcemia, or
             gastrointestinal malabsorptive conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Rita I Young, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ralph H. Johnson VA Medical Center, Charleston, SC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center, Charleston, SC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>September 6, 2016</results_first_submitted>
  <results_first_submitted_qc>October 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2016</results_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcitriol</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication of deidentified results.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Celecoxib</title>
          <description>Treatment with Celecoxib</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Calcitriol</title>
          <description>Treatment with Calcitriol</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Celecoxib Plus Calcitriol</title>
          <description>Treatment with Celecoxib + Calcitriol</description>
        </group>
        <group group_id="P4">
          <title>Arm 4: No Treatment</title>
          <description>no treatment prior to surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Celecoxib</title>
          <description>Celecoxib:
Celecoxib (400 mg twice daily) oral cancer patients receiving new immunotherapy prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Calcitriol</title>
          <description>Calcitriol Calcitriol (1,25-dihydroxyvitamin D3): 3 week pre-surgical enteral treatment of Calcitriol (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment)</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Celecoxib Plus Calcitriol</title>
          <description>Celecoxib + Calcitriol 3 week pre-surgical enteral treatment of Calcitriol (3 cycles of 4 microg 1,25-dihydroxyvitamin D3) for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)</description>
        </group>
        <group group_id="B4">
          <title>Arm 4: No Treatment</title>
          <description>oral cancer patients receiving no immunotherapy prior to surgery</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-2 Levels</title>
        <description>Change in IL-2 stimulatory cytokine levels within tumor tissue.</description>
        <time_frame>baseline and 3 weeks</time_frame>
        <population>Patients with head and neck squamous cell carcinoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Celecoxib</title>
            <description>Celecoxib treatment prior to surgery
Celecoxib: Celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Calcitriol</title>
            <description>Treatment with Calcitriol prior to surgery
Calcitriol: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Celecoxib Plus Calcitriol</title>
            <description>Treatment with Celecoxib plus Calcitriol prior to surgery.
Celecoxib plus Calcitriol: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: No Treatment</title>
            <description>no treatment prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-2 Levels</title>
          <description>Change in IL-2 stimulatory cytokine levels within tumor tissue.</description>
          <population>Patients with head and neck squamous cell carcinoma.</population>
          <units>pg/100 gm protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.3"/>
                    <measurement group_id="O2" value="4.0" spread="0.4"/>
                    <measurement group_id="O3" value="7.9" spread="1.2"/>
                    <measurement group_id="O4" value="2.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>A Student's t test was performed to determine significance of differences between each of two groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IFN-gamma Levels</title>
        <description>Change in IFN-gamma stimulatory cytokine levels within tumor tissue.</description>
        <time_frame>baseline and 3 weeks</time_frame>
        <population>Patients with head and neck squamous cell carcinoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Celecoxib</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
1,25-dihydroxyvitamin D3: 3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Calcitriol</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
celecoxib: celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Celecoxib Plus Calcitriol</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
1,25-dihydroxyvitamin D3 + celecoxib: 3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment) plus celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: No Treatment</title>
            <description>oral cancer patients receiving no immunotherapy prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IFN-gamma Levels</title>
          <description>Change in IFN-gamma stimulatory cytokine levels within tumor tissue.</description>
          <population>Patients with head and neck squamous cell carcinoma.</population>
          <units>pg/100 gm protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.6"/>
                    <measurement group_id="O2" value="2.8" spread="1.1"/>
                    <measurement group_id="O3" value="6.3" spread="2.2"/>
                    <measurement group_id="O4" value="2.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>A Student’s t test was performed to determine significance of differences between each of two groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in GM-CSF</title>
        <description>Change in GM-CSF stimulatory cytokine levels within tumor tissue.</description>
        <time_frame>baseline and 3 weeks</time_frame>
        <population>Patients with head and neck squamous cell carcinoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Celecoxib</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
1,25-dihydroxyvitamin D3: 3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Calcitriol</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
celecoxib: celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Celecoxib Plus Calcitriol</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
1,25-dihydroxyvitamin D3 + celecoxib: 3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment) plus celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: No Treatment</title>
            <description>oral cancer patients receiving no immunotherapy prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GM-CSF</title>
          <description>Change in GM-CSF stimulatory cytokine levels within tumor tissue.</description>
          <population>Patients with head and neck squamous cell carcinoma.</population>
          <units>pg/100 gm protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.4"/>
                    <measurement group_id="O2" value="8.1" spread="1.9"/>
                    <measurement group_id="O3" value="14.3" spread="3.4"/>
                    <measurement group_id="O4" value="3.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>A Student’s t test was performed to determine significance of differences between each of two groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-6 Levels.</title>
        <description>Change in levels of immune inhibitory/inflammatory mediator IL-6 in tumor tissue.</description>
        <time_frame>baseline and 3 weeks</time_frame>
        <population>Patients with head and neck squamous cell carcinoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Celecoxib</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
1,25-dihydroxyvitamin D3: 3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Calcitriol</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
celecoxib: celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Celecoxib Plus Calcitriol</title>
            <description>oral cancer patients receiving new immunotherapy prior to surgery
1,25-dihydroxyvitamin D3 + celecoxib: 3 week pre-surgical enteral treatment of 1,25(OH)2D3 (3 cycles of 4 microg 1,25(OH)2D3 for each of 3 sequential days followed by 4 days of no treatment) plus celecoxib (400 mg twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: No Treatment</title>
            <description>oral cancer patients receiving no immunotherapy prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 Levels.</title>
          <description>Change in levels of immune inhibitory/inflammatory mediator IL-6 in tumor tissue.</description>
          <population>Patients with head and neck squamous cell carcinoma.</population>
          <units>pg/100 gm protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="18"/>
                    <measurement group_id="O2" value="46" spread="21"/>
                    <measurement group_id="O3" value="29" spread="8"/>
                    <measurement group_id="O4" value="132" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>A Student’s t test was performed to determine significance of differences between each of two groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Celecoxib</title>
          <description>oral cancer patients receiving Celecoxib prior to surgery</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Calcitriol</title>
          <description>oral cancer patients receiving Calcitriol prior to surgery</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Celecoxib Plus Calcitriol</title>
          <description>oral cancer patients receiving Celecoxib + Calcitriol prior to surgery</description>
        </group>
        <group group_id="E4">
          <title>Arm 4: No Treatment</title>
          <description>oral cancer patients receiving no treatment prior to surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Difficulty in recruiting subjects that are eligible for the combination Celecoxib + Calcitriol treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>M. Rita I. Young, Ph.D.</name_or_title>
      <organization>Ralph H. Johnson VA Medical Center, Charleston, SC</organization>
      <phone>843-792-9953</phone>
      <email>rita.young@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

